inclusion criteria: 1. willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 2. 18 years of age or older. 3. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay. 4. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of \< 24 hours) 5. the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. 6. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. 7. must have at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19 in the opinion of the investigator. symptom onset must be ≤7 days prior to first dose. subject must have one or more symptoms at first dose. 8. able to swallow capsules.

inclusion criteria: 1. willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 2. 18 years of age or older. 3. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay. 4. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of \< 24 hours) 5. the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. 6. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. 7. must have at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19 in the opinion of the investigator. symptom onset must be ≤7 days prior to first dose. subject must have one or more symptoms at first dose. 8. able to swallow capsules.

inclusion criteria: willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 18 years of age or older. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of < 24 hours) the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. must have at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19 in the opinion of the investigator. symptom onset must be ≤7 days prior to first dose. subject must have one or more symptoms at first dose. able to swallow capsules.

inclusion criteria: willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 18 years of age or older. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of < 24 hours) the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. must have at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19 in the opinion of the investigator. symptom onset must be ≤7 days prior to first dose. subject must have one or more symptoms at first dose. able to swallow capsules.

inclusion criteria: 1. willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 2. 18 years of age or older. 3. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay. 4. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of < 24 hours) 5. the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. 6. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. 7. must have at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19 in the opinion of the investigator. symptom onset must be ≤7 days prior to first dose. subject must have one or more symptoms at first dose. 8. able to swallow capsules.

inclusion criteria: 1. willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 2. 18 years of age or older. 3. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay. 4. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of < 24 hours) 5. the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. 6. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. 7. must have at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19 in the opinion of the investigator. symptom onset must be ≤7 days prior to first dose. subject must have one or more symptoms at first dose. 8. able to swallow capsules.

inclusion criteria: 1. willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 2. 18 years of age or older. 3. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay within 14 days of first dose. 4. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of < 24 hours) 5. the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. 6. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. 7. at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19. 8. able to swallow capsules.

inclusion criteria: 1. willing and able to provide informed consent for the trial, written, electronic, verbal or other method deemed acceptable by the institution and irb. 2. 18 years of age or older. 3. laboratory-confirmed sars-cov-2 infection as determined by real time polymerase chain reaction (rt-pcr) or other fda-approved commercial or public health assay within 14 days of first dose. 4. out-patient (never hospitalized as an in-patient for covid-19 or was evaluated/treated for covid-19 only in the emergency room with a stay of < 24 hours) 5. the effects of brequinar on the developing human fetus are unknown. for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. men and women treated or enrolled on this protocol must also agree to use adequate contraception for the duration of study participation, and for 90 days after completion of brequinar administration. 6. male subjects must agree to refrain from sperm donation and female subjects must agree to refrain from ovum donation from initial study drug administration until 90 days after the last dose of brequinar. 7. at least one covid-19 symptom including but not limited to fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with covid-19. 8. able to swallow capsules.